Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$140.56 USD
-0.87 (-0.62%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $140.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SRPT 140.56 -0.87(-0.62%)
Will SRPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
Other News for SRPT
Biotech Alert: Searches spiking for these stocks today
These are the stocks with the largest changes in short interest in July - GS
Video: Tuesday 8/20 Insider Buying Report: SRPT, ALGN
AVK: Trying To Take Advantage Of Market Developments, But Hard To Justify A Premium
How Is The Market Feeling About Sarepta Therapeutics?